Eun Jung Song;Mi La Cho;Jin Sil Park;Eun Kyung Lee;Hye Jwa Oh;Kyu Won Cho;Ki Won Jo;Young Woo Park;Jin Mi Oh;Ho Youn Kim;Dong Ji Kim;Sun-Ha Yoon;Srok Ho Yoo;Jae Kyeong;Yun Ju Woo;Jung Yu;Mi Kyung Park
发明人:
Young Woo Park,Ki Won Jo,Srok Ho Yoo,Jung Yu,Dong Ji Kim,Sun-Ha Yoon,Eun Jung Song,Eun Kyung Lee,Jin Mi Oh,Kyu Won Cho,Mi La Cho,Ho Youn Kim,Mi Kyung Park,Hye Jwa Oh,Jin Sil Park,Yun Ju Woo,Jae Kyeong
申请号：
US13635868
公开号：
US20130017226A1
申请日:
2011.03.18
申请国别(地区):
US
年份:
2013
代理人:
摘要：
The present invention relates to TNFR2-TWEAKR fusion protein, more precisely to TNFR2-TWEAKR fusion protein acting as a double-antagonist to TNF-α and TWEAK, known as major causes of autoimmune arthritis which is one of autoimmune diseases. When the composition comprising TNFR2-TWEAKR fusion protein was treated to Th17 cells, the secretion of the inflammatory cytokine IL-17 was reduced but the secretion of the anti-inflammatory cytokine IL-10 generated in Treg cells was increased. Such effect of TNFR2-TWEAKR fusion protein was far greater than that of a single protein such as TNFR2-Fc or TWEAK-Fc. The TNFR2-TWEAKR fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-TWEAKR fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease.
